Oncolytics Biotech
ONCY
33 hedge funds and large institutions have $823K invested in Oncolytics Biotech in 2020 Q1 according to their latest regulatory filings, with 12 funds opening new positions, 4 increasing their positions, 6 reducing their positions, and 5 closing their positions.
140% more first-time investments, than exits
New positions opened: 12 | Existing positions closed: 5
18% more funds holding
Funds holding: 28 → 33 (+5)
0.52% more ownership
Funds ownership: 1.08% → 1.6% (+0.52%)
33% less repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 6
56% less capital invested
Capital invested by funds: $1.86M → $823K (-$1.04M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Two Sigma Advisers
New York
|
+$376K |
| 2 |
Creative Planning
Overland Park,
Kansas
|
+$232K |
| 3 |
WS
Wedbush Securities
Los Angeles,
California
|
+$112K |
| 4 |
Renaissance Technologies
New York
|
+$105K |
| 5 |
BBVA
Banco Bilbao Vizcaya Argentaria
Madrid,
Spain
|
+$74.9K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
-$341K |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$154K |
| 3 |
Jane Street
New York
|
-$69K |
| 4 |
FDCDDQ
Federation des caisses Desjardins du Quebec
Levis,
Quebec, Canada
|
-$19K |
| 5 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
-$13K |
ONCY Hedge Fund Activity: Q1 2020 in Review
33 of the 4,548 institutional investors tracked by Wall St. Rank reported a position in Oncolytics Biotech (ONCY) for Q1 2020, worth a combined $823K — down 56% from $1.86M a quarter earlier.
Buyers outnumbered sellers: 12 funds opened new ONCY positions and 5 closed out — a net gain of 7 holders — while 4 added to existing stakes and 6 trimmed.
The largest buyer was Two Sigma Advisers, opening a new position worth an estimated $376K. The largest seller was Morgan Stanley, cutting an estimated $341K.
- 33 institutional investors held Oncolytics Biotech (ONCY) as of Q1 2020, up from 28 in Q4 2019.
- Funds reported $823K of Oncolytics Biotech stock for Q1 2020, down 56% quarter-over-quarter.
- 12 funds opened new Oncolytics Biotech positions in Q1 2020 and 5 closed out, a net change of +7 holders.
- The largest Oncolytics Biotech buyer in Q1 2020 was Two Sigma Advisers, an estimated $376K added.
- The largest Oncolytics Biotech seller in Q1 2020 was Morgan Stanley, an estimated $341K sold.
Based on aggregated 13F filings for Q1 2020.